Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Kim K, Maiti A, Loghavi S, Pourebrahim R, et al. Cancer 2021 Jul 13. doi: 10.1002/cncr.33689.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim K, Maiti A, Loghavi S, Pourebrahim R, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 2021 Jul 13. doi: 10.1002/cncr.33689.
PMID: 34255353